Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), ...

Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage ...

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a biotech firm, has received FDA clearance for a Phase 2 trial of DNTH103 in Multifocal Motor Neuropathy ...